ArticleBrazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica2017
Performance of urinary kidney injury molecule-1, neutrophil gelatinase-associated lipocalin, and N-acetyl-β-D-glucosaminidase to predict chronic kidney disease progression and adverse outcomes.
Article in Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Evaluation of N-acetyl-β-D-glucosaminidase as a prognostic marker for diabetic nephropathy in type 2 diabetics: systematic review and meta-analysis.International urology and nephrology · 2024Pooled it
- Fruits Granola Consumption May Contribute to a Reduced Risk of Cardiovascular Disease in Patients with Stage G2-4 Chronic Kidney Disease.Foods (Basel, Switzerland) · 2025Article
- Pathophysiological Link and Treatment Implication of Heart Failure and Preserved Ejection Fraction in Patients with Chronic Kidney Disease.Biomedicines · 2024Review
- Biomarkers of chronic kidney disease in older individuals: navigating complexity in diagnosis.Frontiers in medicine · 2024Review
- Revisiting the Role of NAG across the Continuum of Kidney Disease.Bioengineering (Basel, Switzerland) · 2023Review
- Novel Biomarkers of Kidney Disease in Advanced Heart Failure: Beyond GFR and Proteinuria.Current heart failure reports · 2022Review
- SGLT2 inhibitors in the treatment of type 2 cardiorenal syndrome: Focus on renal tubules.Frontiers in nephrology · 2022Review
- Soluble Interleukin-2 Receptor Predicts Treatment Outcome in Patients With Autoimmune Tubulointerstitial Nephritis. A Preliminary Study.Frontiers in medicine · 2022Article
- Pathomechanisms in the Kidneys in Selected Protozoan Parasitic Infections.International journal of molecular sciences · 2021Review
- The ratio and difference of urine protein-to-creatinine ratio and albumin-to-creatinine ratio facilitate risk prediction of all-cause mortality.Scientific reports · 2021Article
- Biomarkers of kidney injury among children in a high-risk region for chronic kidney disease of uncertain etiology.Pediatric nephrology (Berlin, Germany) · 2021Article
- Urine NGAL and KIM-1-Tubular Injury Biomarkers in Long-Term Survivors of Childhood Solid Tumors: A Cross-Sectional Study.Journal of clinical medicine · 2021Article
- New Potential Biomarkers for Chronic Kidney Disease Management-A Review of the Literature.International journal of molecular sciences · 2020Review
- Urine NGAL and KIM-1: tubular injury markers in acute lymphoblastic leukemia survivors.Cancer chemotherapy and pharmacology · 2020Observational
- The association of renal tubular inflammatory and injury markers with uric acid excretion in chronic kidney disease patients.International urology and nephrology · 2020Article
- Article
- Renal injury after uninephrectomy in male and female intrauterine growth-restricted aged rats.PloS one · 2019Article
- Urinary Neutrophil Gelatinase Associated Lipocalin as a Marker of Nephropathy in Type 2 Diabetic Patients.Indian journal of nephrologyArticle
- Uric Acid Lowering and Biomarkers of Kidney Damage in CKD Stage 3: A Post Hoc Analysis of a Randomized Clinical Trial.Kidney medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Urinary biomarkers can predict the progression of chronic kidney disease (CKD). In this study, kidney injury molecule-1 (KIM-1), neutrophil gelatinase-associated lipocalin (NGAL), and N-acetyl-β-D-glucosaminidase (NAG) were correlated with the stages of CKD, and the association of these biomarkers with CKD progression and adverse outcomes was determined. A total of 250 patients, including 111 on hemodialysis, were studied. Urinary KIM-1, NGAL, and NAG were measured at baseline. Patients not on dialysis at baseline who progressed to a worse CKD stage were compared with those who did not progress. The association of each biomarker and selected covariates with progression to more advanced stages of CKD, end-stage kidney disease, or death was evaluated by Poisson regression. NGAL was moderately correlated (rs=0.467, P<0.001) with the five stages of CKD; KIM-1 and NAG were also correlated, but weakly. Sixty-four patients (46%) progressed to a more advanced stage of CKD. Compared to non-progressors, those patients exhibited a trend to higher levels of KIM-1 (P=0.064) and NGAL (P=0.065). In patients not on dialysis at baseline, NGAL was independently associated with progression of CKD, ESKD, or death (RR=1.022 for 300 ng/mL intervals; CI=1.007-1.037, P=0.004). In patients on dialysis, for each 300-ng/mL increase in urinary NGAL, there was a 1.3% increase in the risk of death (P=0.039). In conclusion, urinary NGAL was associated with adverse renal outcomes and increased risk of death in this cohort. If baseline urinary KIM-1 and NGAL predict progression to worse stages of CKD is something yet to be explored.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.